Bracco Spa, Milan: transmission to the Ministero della sanità, Direzione Generale del Servizio farmaceutico of three new protocols, accompanied by B-sheets for the start of clinical trials, relating to the pharmaceutical product "Remoxipride" capsules 75, 150, 300 mg, oral suspension 25 mg./ml., vials 1-2 ml. (100 mg./ml.), controlled-release capsules 150 and 300 mg.